Navigation Links
Statement from the Cystic Fibrosis Foundation on Promising Phase 2 Clinical Trial Results of Kalydeco and VX-661 (Vertex Pharmaceuticals Inc.)
Date:4/19/2013

BETHESDA, Md., April 19, 2013 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation issued the following statement in response to an announcement by Vertex Pharmaceuticals Inc. regarding promising results from a Phase 2 clinical trial of its cystic fibrosis drug Kalydeco™ in combination with another potential CF therapy, VX-661. The results showed a significant improvement in lung function in people with two copies of the most common CF mutation, Delta F508, who took the combination treatment, compared with those who received a placebo. About 50 percent of people with CF in the United States have two copies of the Delta F508 mutation.

Both Kalydeco and VX-661 are designed to treat the underlying cause of CF, a faulty gene and its protein product, known as CFTR.

"This announcement is more terrific news for the CF community," said Robert J. Beall , Ph.D., president and CEO of the Cystic Fibrosis Foundation. "While these results are still very early, they show that another potential therapy from our ongoing collaboration with Vertex can be combined with Kalydeco to achieve promising improvements in health. The data further validate our strategy of using small molecule compounds to address the basic genetic defect in cystic fibrosis."

The CF Foundation played a key role in the development of Kalydeco and VX-661, as well as other experimental compounds such as VX-809, providing significant scientific, clinical and financial support. Vertex is studying Kalydeco with VX-809 in Phase 3 trials that will enroll about 1,000 people at approximately 200 clinical trial sites in North America, Europe and Australia. "The CF Foundation is deeply grateful to the people with CF, families and medical professionals who have played a role in these studies, and to the Vertex scientists who remain dedicated to advancing CF drug development," said Beall.

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The CF Foundation is a donor-supported nonprofit organization. For more information, go to www.cff.org.


'/>"/>
SOURCE Cystic Fibrosis Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Alarm Concepts Files Information Statement and Provides Update on Corporate Activity
2. Joint Statement On The Presidents Budget From The American Society Of Clinical Oncology, Community Oncology Alliance, ION Solutions and The US Oncology Network
3. Receptos Files Registration Statement for Proposed Initial Public Offering
4. Star Scientific, Inc. Issues Statement in Response to Two Plaintiffs Purported Class Action Law Suits and Multiple Press Releases Issued by Plaintiffs Law Firms Trolling for New Clients
5. National Cancer Organizations Issue Joint Statement On Devastating Impact Of Sequestration
6. AUGS Issues Statement Opposing The Restriction Of Surgical Options For Pelvic Floor Disorders
7. Bausch + Lomb Files Registration Statement For Proposed Initial Public Offering
8. CHPA Statement on Statewide South Carolina Consumer Poll
9. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
10. Chimerix Files Registration Statement for Proposed Initial Public Offering
11. CHPA Statement on PSE Economic Study By AEI Fellow Alex Brill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... 2017  National Decision Support Company (NDSC) announces ... CareSelect Imaging platform within the full range of ... technical foundation for MEDITECH sites, through a directly ... Decision Support Mechanism through the MEDITECH EHR. ... support the integration of NDSC,s mechanism, which enables ...
(Date:2/20/2017)... , Feb. 20, 2017 Research and Markets ... Market: Insights, Opportunity, Analysis, Market Shares & Forecast 2017 - 2022" ... ... reach nearly USD 2 Billion by the year end of 2022 ... Market growth can be attributed to factors such ...
(Date:2/20/2017)... , Feb. 20, 2017   Orion Health ... its Amadeus precision medicine platform to the ... currently manages over 110 million patient records globally. ... developing cloud-based, big data solutions built on modern, scalable ... Healthcare and Life Sciences. "The AWS Cloud gives healthcare ...
Breaking Medicine Technology:
(Date:2/18/2017)... ... ... Park Cities Pet Sitter President, Joette White, has been featured on Episode ... The episode, which was posted this week, features a 30-minute interview of White by ... Pet Sitter’s being awarded the 2017 National Association of Professional Pet Sitter’s Business of ...
(Date:2/17/2017)... TN (PRWEB) , ... February 17, 2017 , ... ... mobility has not kept pace. Enovate Medical has introduced an innovative workstation designed ... years of supporting nurses, the Encore Mobile EHR Workstation offers a lightweight, highly ...
(Date:2/17/2017)... Church, VA (PRWEB) , ... ... ... Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. 22, ... , What are the critical reimbursement questions manufacturers should be asking before ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... at the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to ... of the most widely used electronic patient signatures solution in healthcare . ...
(Date:2/17/2017)... ... February 17, 2017 , ... PrideStaff, a national ... was named to Staffing Industry Analysts' 2017 "Staffing 100 North America" list. ... made notable contributions to the staffing industry over the last twelve months. Industry ...
Breaking Medicine News(10 mins):